Azacitidine holds promise in VEXAS syndrome; a step forward in precision blood matching; identifying a new vulnerability in TP53-mutated AML
This episode discusses the potential of Azacitidine in treating VEXAS syndrome, advancements in precision blood matching using array genotyping, and the identification of a new vulnerability in TP53-mutated AML related to BAP1 loss, which may guide therapeutic strategies.